Characterization of [3H]LUF5834: A novel non-ribose high-affinity agonist radioligand for the adenosine A1 receptor

Biochemical Pharmacology

Volumn 80, Issue 8, 2010, Pages 1180-1189

  Lane, J Robert ^a   Klaasse, Elisabeth ^a   Lin, Judy ^a   van Bruchem, John ^a   Beukers, Margot W ^a   IJzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adenosine receptor; G protein coupled receptor; Inverse agonist; Partial agonist; Radioligand

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; C8 ETHYLAMINO N 6 CYCLOPENTYLADENOSINE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; LUF 5834; N 0840; RADIOLIGAND; UNCLASSIFIED DRUG; 2 AMINO 4 (4 HYDROXYPHENYL) 6 (1H IMIDAZOL 2 YLMETHYLSULFANYL)PYRIDINE 3,5 DICARBONITRILE; 2-AMINO-4-(4-HYDROXYPHENYL)-6-(1H-IMIDAZOL-2-YLMETHYLSULFANYL)PYRIDINE-3,5-DICARBONITRILE; ADENINE; ADENOSINE A2B RECEPTOR; AMINOPYRIDINE DERIVATIVE; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; ISOTHERM; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; METABOLISM; RADIOASSAY;

ADENINE; AMINOPYRIDINES; ANIMALS; CELL LINE; CELL MEMBRANE; CRICETINAE; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2B;

EID: 77956227011     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.041     Document Type: Article

References (29)

1. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53:527-552.
2. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996, 118:1461-1468.
3. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006, 5:247-264.
4. Gao Z.G., Jacobson K.A. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 2007, 12:479-492.
5. Peterman C., Sanoski C.A. Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev 2005, 13:315-321.
6. Elzein E., Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 2008, 17:1901-1910.
7. Muller C.E. Adenosine receptor ligands-recent developments part I. Agonists. Curr Med Chem 2000, 7:1269-1288.
8. Soudijn W., van Wijngaarden I., IJzerman A.P. Medicinal chemistry of adenosine A1 receptor ligands. Curr Top Med Chem 2003, 3:355-367.
9. Rosentreter U, Kraemer T, Shimada M, Huebsch W, Diedrichs N, Krahn T, et al. Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands. WO patent 2003/03008384 (2003).
10. Rosentreter U, Kramer T, Shimada M, Hubsch W, Diedrichs N, Krahn T, et al. Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands. US patent 2004/0176417 (2004).
11. Beukers M.W., Chang L.C., von Frijtag Drabbe Kunzel J.K., Mulder-Krieger T., Spanjersberg R.F., Brussee J., et al. New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 2004, 47:3707-3709.
12. Chang L.C., von Frijtag Drabbe Kunzel J.K., Mulder-Krieger T., Spanjersberg R.F., Roerink S.F., van den Hout G., et al. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem 2005, 48:2045-2053.
13. Heitman L.H., Mulder-Krieger T., Spanjersberg R.F., von Frijtag Drabbe Kunzel J.K., Dalpiaz A., IJzerman A.P. Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist. Br J Pharmacol 2006, 147:533-541.
14. Roelen H., Veldman N., Spek A.L., von Frijtag Drabbe Kunzel J., Mathot R.A., IJzerman A.P. N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors. J Med Chem 1996, 39:1463-1471.
15. Klotz K.N., Lohse M.J., Schwabe U., Cristalli G., Vittori S., Grifantini M. 2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CCPA)-a high affinity agonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1989, 340:679-683.
16. Lohse M.J., Klotz K.N., Lindenborn-Fotinos J., Reddington M., Schwabe U., Olsson R.A. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)-a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1987, 336:204-210.
17. Kourounakis A., Visser C., de Groote M., IJzerman A.P. Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. Biochem Pharmacol 2001, 61:137-144.
18. Lopez-Gimenez J.F., Villazon M., Brea J., Loza M.I., Palacios J.M., Mengod G., et al. Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists. Mol Pharmacol 2001, 60:690-699.
19. Newman-Tancredi A., Verriele L., Chaput C., Millan M.J. Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. Naunyn Schmiedebergs Arch Pharmacol 1998, 357:205-217.
20. Sundaram H., Turner J.D., Strange P.G. Characterisation of recombinant serotonin 5-HT1A receptors expressed in Chinese hamster ovary cells: the agonist [3H]lisuride labels free receptor and receptor coupled to G protein. J Neurochem 1995, 65:1909-1916.
21. Milligan G. Principles: extending the utility of [35S]GTP gamma S binding assays. Trends Pharmacol Sci 2003, 24:87-90.
22. Samama P., Cotecchia S., Costa T., Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 1993, 268:4625-4636.
23. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002, 54:323-374.
24. Shryock J.C., Ozeck M.J., Belardinelli L. Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol 1998, 53:886-893.
25. de Ligt R.A., IJzerman A.P. Intrinsic activity at adenosine A1 receptors: partial and inverse agonism. Curr Pharm Des 2002, 8:2333-2344.
26. Christopoulos A., El-Fakahany E.E. Qualitative and quantitative assessment of relative agonist efficacy. Biochem Pharmacol 1999, 58:735-748.
27. Newman-Tancredi A., Verriele L., Touzard M., Millan M.J. Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. Eur J Pharmacol 2001, 428:177-184.
28. Newman-Tancredi A., Verriele L., Millan M.J. Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635. Br J Pharmacol 2001, 132:518-524.
29. Ribeiro J.A., Sebastiao A.M., de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 2002, 68:377-392.